双鹭药业
(002038)
| 流通市值：56.12亿 | | | 总市值：67.70亿 |
| 流通股本：8.52亿 | | | 总股本：10.27亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 168,896,131.59 | 660,419,604.31 | 540,562,431.05 | 392,063,433.48 |
| 营业收入 | 168,896,131.59 | 660,419,604.31 | 540,562,431.05 | 392,063,433.48 |
| 二、营业总成本 | 155,955,363.45 | 621,412,318.94 | 461,951,501.39 | 261,700,152.08 |
| 营业成本 | 68,792,328.23 | 211,533,255.13 | 170,782,084.55 | 89,873,996.9 |
| 税金及附加 | 741,836.69 | 7,785,648.98 | 5,073,775.28 | 4,127,487.37 |
| 销售费用 | 19,904,477.41 | 117,181,775.5 | 91,222,553.23 | 48,797,538.62 |
| 管理费用 | 38,850,701.09 | 142,731,340.59 | 101,968,231.45 | 65,914,589.1 |
| 研发费用 | 28,942,931.49 | 149,623,443.03 | 98,929,930.35 | 57,415,748.19 |
| 财务费用 | -1,276,911.46 | -7,443,144.29 | -6,025,073.47 | -4,429,208.1 |
| 其中:利息收入 | 1,315,341.56 | 8,396,576.28 | 6,565,621.23 | 4,841,684.63 |
| 加:公允价值变动收益 | 25,524,228.94 | -172,293,877.63 | -121,662,443.96 | -118,495,945.17 |
| 加:投资收益 | 5,591,921.67 | 13,127,545.13 | 18,516,475.89 | 14,684,499.66 |
| 资产处置收益 | - | - | 1,142.29 | 507.6 |
| 资产减值损失(新) | - | -556,697.75 | - | - |
| 信用减值损失(新) | 282,246.51 | -11,092,825.48 | -13,442,742.02 | -13,375,014.04 |
| 其他收益 | 4,006,991.45 | 12,205,218.38 | 5,661,293.9 | 5,307,446.48 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 48,346,156.71 | -119,603,351.98 | -32,315,344.24 | 18,484,775.93 |
| 加:营业外收入 | 0.23 | 70,826.98 | 1.12 | 0.02 |
| 减:营业外支出 | 323,036 | 14,217,127.64 | 4,851,464.01 | 2,944.21 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 48,023,120.94 | -133,749,652.64 | -37,166,807.13 | 18,481,831.74 |
| 减:所得税费用 | 2,405,937.61 | -58,462,889.66 | -19,420,932.88 | -10,302,320.25 |
| 六、净利润 | 45,617,183.33 | -75,286,762.98 | -17,745,874.25 | 28,784,151.99 |
| 持续经营净利润 | 45,617,183.33 | -75,286,762.98 | -17,745,874.25 | 28,784,151.99 |
| 归属于母公司股东的净利润 | 45,968,405.62 | -74,065,657.76 | -16,735,581.13 | 29,590,001.31 |
| 少数股东损益 | -351,222.29 | -1,221,105.22 | -1,010,293.12 | -805,849.32 |
| (一)基本每股收益 | 0.04 | -0.07 | -0.02 | 0.03 |
| (二)稀释每股收益 | 0.04 | -0.07 | -0.02 | 0.03 |
| 九、综合收益总额 | 45,617,183.33 | -75,286,762.98 | -17,745,874.25 | 28,784,151.99 |
| 归属于母公司股东的综合收益总额 | 45,968,405.62 | -74,065,657.76 | -16,735,581.13 | 29,590,001.31 |
| 归属于少数股东的综合收益总额 | -351,222.29 | -1,221,105.22 | -1,010,293.12 | -805,849.32 |
| 公告日期 | 2025-04-22 | 2025-04-22 | 2024-10-26 | 2024-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |